This post was originally published on this site
The company also released its 2023 revenue forecast on Tuesday, months after raising doubts about its ability to remain in business, and announced about $800 million in conditional ex-U.S. purchase contracts for its COVID shot for the year.
It now expects 2023 revenue between $1.4 billion and $1.6 billion, compared with expectations of $831.6 million, according to five analysts polled by Refinitiv.
Novavax (NASDAQ:NVAX), whose coronavirus vaccine is its lone marketed product after 35 years in business, is now banking on its cost-control measures and a successful trial for its COVID/flu combination vaccine candidate to help it stay afloat.
Data from a mid-stage trial in adults aged 50 to 80 years showed that the combination shot produced an immune response comparable to its protein-based COVID vaccine and already approved influenza shots.
The new data comes at a time when global regulators expect COVID vaccination campaigns to be conducted annually like flu inoculations.
Novavax said the mid-stage data supports further development of its COVID/flu vaccine and a standalone flu shot, for which it will seek potential partnerships.
The layoffs, part of its ongoing cost-reduction measures, would impact about 20% of the 1,959 full-time employees it had as of April 18, or about 392 jobs. The remaining 5% would consist of contractual employees.
The biotech expects the cost cuts to reduce its annual research and commercial expenses by 20% to 25% from last year.
Its cash and equivalents fell to $637 million at quarter-end from $1.3 billion as of Dec. 31.
Novavax also posted a first-quarter net loss of $3.41 per share, compared with estimates of $3.46.
